Slides
Page 1
October 2026 Global Leader in Relapsed/Refractory AL Amyloidosis This presentation contains NEXICART-2 clinical data update on pages 19-24
Page 2
2 Disclaimer: Forward Looking Statements & Market Data This presentation contains forward-looking statements that involve substantial risks and uncertainties. All statements, other than statements of historical facts, contained in this presentation, including statements regarding Immix Biopharma, Inc.’s (the “Company”) strategy, future operations, future financial position, projected costs, prospects, plans, and objectives of management, are forward-looking statements. The words ‘‘anticipate,’’ ‘‘believe,’’ ‘‘continue,’’ ‘‘could,’’ “depends,” ‘‘estimate,’’ ‘‘expect,’’ ‘‘intend,’’ ‘‘may,’’ “ongoing,” ‘‘plan,’’ ‘‘potential,’’ ‘‘predict,’’ ‘‘project,’’ ‘‘target,’’ ‘‘should,’’ “will,” ‘‘would,’’ and similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain these identifying words. The Company may not actually achieve the plans, intentions, or expectations disclosed in these forward-looking statements, and you should not place undue reliance on these forward-looking statements. Actual results or events could differ materially from the plans, intentions and expectations disclosed in these forward-looking statements. In addition, the forward-looking statements included in this presentation represent the Company’s views as of the date of this presentation. The Company anticipates that subsequent events and developments will cause its views to change. However, while the Company may elect to update these forward-looking statements at some point in the future, it specifically disclaims any obligation to do so. These forward-looking statements should not be relied upon as representing the Company’s views as of any date subsequent to the date of this presentation. This presentation also includes data from other approved therapies and in trials, which are generated from separate, independent studies and do not come from head-to-head analysis. Differences exist between study or trial designs and subject characteristics, and caution should be exercised when comparing data across studies sourced from publicly available sources. This presentation also contains estimates and other statistical data made by independent parties and by us relating to market size and growth and data about our industry. This data involves a number of assumptions and limitations, and you are cautioned not to give undue weight to such estimates. In addition, projections, assumptions, and estimates of our future performance and the future performance of the markets in which we operate are necessarily subject to a high degree of uncertainty and risk. These and other factors could cause results to differ materially from those expressed in the estimates made by the independent parties and by us.
Page 3
The moment every doctor and family dreads… “There’s nothing more we can do.” In AL amyloidosis, that sentence has been delivered to approximately 30,506 patients living in the U.S. today Source: 30,506 – prevalence = patients eligible for treatment with NXC-201 as of 2026 which excludes 1,271 mayo stage 3b (4%, Zanwar et al.) / 5.9 years average survival (Staron et al.) = 5,389 annual incidence (Laires et al.) Laires P. et al. Incidence and Prevalence of Light Chain Amyloidosis in the United States in 2019-2021 Using Optum EHR Data. Nature 2025. 5,386 = 20.2 incidence per U.S. adults. 20.2 = 16.7 per million U.S. adults in 2021 cited in Laires et al. grown to20.2 over 5 years at half the Laires et al. cited CAGR (7.7% / 2 = 3.9%). Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer Journal. 2021;11:139.
Page 4
I’ve been the doctor in that room. I’ve watched hope disappear. And I couldn’t accept that suffering was “standard of care.” Ilya Rachman, MD, PhD Chief Executive Officer, Founder
Page 5
When your immune system becomes your killer One week of antibody production clears a cold/flu like a superhero Source: Kyu S. et al. Frequencies of Human Influenza-specific Antibody Secreting Cells or Plasmablasts post Vaccination from Fresh and Frozen Peripher al Blood Mononuclear Cells. J Immunol Methods. 2015. Mutations cause continuously produced antibodies to flood organs with toxic light chains, transforming into supervillains X✓
Page 6
The Toxic Last Ditch Effort A single FDA approval – a 4-drug combination – exists, for newly diagnosed patients only. And it doesn’t work for everyone. Once relapse hits, there's nothing FDA approved. Then, doctors resort to off-label drug use, despite their limited efficacy Note: ~2/3 of patients are estimated to require a second -line therapy after the FDA -approved 4-drug combination Source: Daratumumab: 1) Bellofiore C, et al. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematol Oncol. 2024. 2) Chakraborty R et al, Reduced early mortality with Daratumumab-based frontline therapy in AL amyloidosis: A retrospective cohort study. AJH 2024. 3) Bazarbachi AH et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. Am J Hematol. 2024 Nov;99(11):2225-2228. doi: 10.1002/ajh.27450. Epub 2024 Aug 3. PMID: 39096115.
Page 7
Normal zone AL Amyloidosis Response Rate After The 4-Drug Combination Fails Note: R/R AL investigator's choice therapies included: Dara -VCd, Dara-Vd, Dara-VRd, Dara-Dex, Dara-Cd, Dara-Pom-Dex, Bendamustine-Dex. Source: Bazarbachi AH et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. Am J Hematol. 2024 Nov;99(11):2225-2228. doi: 10.1002/ajh.27450. Epub 2024 Aug 3. PMID: 39096115. Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. Normal dFLC: <10 mg/L. 12 PATIENT SERIES RELAPSED/REFRACTORY AL AMYLOIDOSIS RECEIVING SECOND LINE THERAPY IN US 1 2 3 4 5 6 7 8 9 10 11 12 Patient 1 2 3 4 5 6 7 8 9 10 11 12 Disease burden at 2nd line therapy dosing: dFLC (mg/L) % Decline in disease burden (dFLC) after 2nd line therapy is dosed (best response to 2nd line therapy) ✓-100% Not CR Death due to Disease 11 out of 12 Remission: No Symptoms 1 out of 12 There are no drugs approved in relapsed/refractory AL amyloidosis. Current investigators' choice agents produce an unsatisfactory reduction in AL amyloidosis disease markers (dFLC) with a low (0-10%) complete response (CR) rate
Page 8
AL Amyloidosis: 30,506 Relapsed/Refractory U.S. Patients with No FDA Approved Drugs Note: Prevalence up to 38,000 according to Quock T et al, Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood 2018. Source: Merlini, G., et al. Nat Rev Dis Primers. Oct 2018, Front. Cardiovasc. Med., Dec 2022, Hemato 2022, 3(1), 47-62. Lu R, Richards TA. AL Amyloidosis: Unfolding a Complex Disease. J Adv Pract Oncol. 2019;10(8):813-825. Quock T et al, Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood 2018. Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer Journal. 2021;11:139. Bone marrow Circulation Target tissues Light chains • Heart failure • Dangerous, irregular rhythms • Difficulty breathing • Low blood pressure Heart Kidney • Kidney failure • Elevated protein in the urine • Swelling of the limbs Liver • Enlarged liver • Abnormal enzyme levels Sheet of misfolded light chains (amyloid) Light chains misfold and aggregate Light chains deposit in organs, damaging organs BCMA receptor NXC-201 TARGETS BCMA RECEPTOR ON PLASMA CELLS, ELIMINATING SOURCE OF LIGHT CHAINS Light chains produced by dysfunctional plasma cells in bone marrow Bone marrow plasma cells Pre-existing heart failure caused by AL Amyloidosis (immediately prior to heart transplant) Example: human heart destroyed by toxic light chains… dFLC (mg/L) 20mg/L X NXC-201 TARGETS PLASMA CELLS THAT CONTINUOUSLY PRODUCE TOXIC LIGHT CHAINS … Driven by persistent elevated toxic light chain levels, despite treatment
Page 9
We’re developing a breakthrough with the goal to change that hopeless sentence Our mission is simple: Create medicines that work without destroying the person.
Page 10
10 NXC-201 sterically-optimized CAR-T’s “Digital Filter”…. …reduces non-specific activation CD8 Signaling Protein COBRA BinderCD8 Hinge4-1BBCD3ζγ CD8 Transmembrane Protein Sterically-optimized key construct modifications 1 Proprietary Optimized CD3 – “CD3ζγ” 2 Proprietary Optimized CD8 Hinge Flexibility 3 Proprietary Optimized COBRA Binder ✓ Delivers “Digital” Intracellular Signaling ✓ Enhances Cytotoxicity ✓ Enables High Expansion ✓ Reduces cytokine release NXC-201 CAR-T 10 The Science That Enables Our Platform “Single amino acid substitutions at key sites can affect CAR-T function over 200-fold range” Ex-NCI/NIH Immix academic researchers ambitiously formulated a thesis: can cell therapy be expanded to a broader patient population, beyond cancer? Result: Sterically-optimized NXC-201 Decreased CD8 hinge flexibility … led to reduced tonic signaling Ex-NIH/NCI Immix academic researchers tuned hinge and transmembrane to reduce tonic immune response(1) 216,05 8 8,016 >90% reduction in IFNγ (pg/mL): K562-BCMA co-culture bb2121 (Abecma) NXC-201 “In activated T cells, the CD3ζ chain gets ubiquitinated by CBLB at its multiple lysine residues and induces degradation of surface TCRs” doi: 10.1038/s41392-021-00823-w “We hypothesized that the redundancy of CD28 and CD3ζ signaling in a chimeric antigen receptor (CAR) design incorporating all three CD3ζ immunoreceptor tyrosine-based activation motifs (ITAMs)11,13 may foster counterproductive T cell differentiation and exhaustion. Therefore, we calibrated ITAM activity by mutating tyrosine residues to impede their phosphorylation and downstream signaling” doi: 10.1038/s41591-018-0290-5 Impeded phosphorylation of ITAM1, added ubiquitination site… led to “digital” quick on/off Sterically-Optimized Binder … led to enhanced cytotoxicity 2 3.6 76 80 HSL VH (GGGGS5) VL LSH VL (GGGGS5) VH Sterically-Optimized Heavy Chain – Proprietary Linker – Light Chain … Day 10 CAR-T Expansion (107) Specific Cytotoxicity (%): target cell co-culture LSH HSLLSH HSL … Results in Superior CAR-T Expansion and Specific Cytotoxicity 4-1BB ICD ITAM domain Immune Reactivity Result of Steric Optimization: (1) (2) Source: E. Lebel, et, al. Safety And Efficacy of a Locally Produced Novel Anti-BCMA Chimeric Antigen Receptor T-Cell (CART) (HBI0101)for the Treatment of Relapsed and Refractory Multiple Myeloma. 65th ASH Annual Meeting and Exposition,San Diego, CA. December 2023.Ying Z, et al. Nat Med. 2019; Schuster SJ, et al. N Engl J Med. 2019; Assayag,M., et al EBMT 2023; Abecma FDA label; Harush O, et al. Haematologica. 2022; Friedman KM, et al. Hum Gene Ther. 2018. Kymriah: Preclinical is an average of CD8+ and CD4+ T-cells, source: Milone MC, et. Al. Mol Ther. 2009 Aug;17(8):1453-64.doi: 10.1038/mt.2009.83.Epub 2009 Apr 21. Erratum in: Mol Ther. 2015 Jul;23(7):1278.PMID: 19384291;PMCID: PMC2805264.*1 Day CRS occurred in high dose MM cohort as of EBMT 2023. NXC-201in multiple myeloma data from ASH 2023 95% ORR in patients without prior anti-BCMA therapy exposure.Moreno-Cortes E,. et al Front Oncol. 2023; Mazinani M, et al. BiomarkRes. 2022.Moreno-Cortes E, et al. ICOS and OX40 tandem co-stimulation enhances CAR T-cell cytotoxicity and promotes T-cell persistence phenotype. Frontiers in Oncology. 2023. Note:; (1) Li, J., Chen, Y., & Zhao, H. (2023).Advancesin targeted therapy for triple-negative breast cancer. Frontiers in Oncology, 13, 10316256.;(2) Friedman KM et al. Hum Gene Ther., 592 (Figure C), 2018. Per ruler measurements, the BB2121 bar measures to 216,058 pg/ML (converted from the ng/ml measurement shown in the Figure). (3) Harush O, et al. Haematologica, 2398 (Figure A), 2022. Per ruler measurements, the H8BB bar measures to 8,016 pg/mL.
Page 11
11 Extraordinary Results in Clinical Trials Relapsed/refractory AL Amyloidosis - Market Situation Current Standards of Care NXC-201 0-10% complete response rate (standard of care) Note: R/R AL current standard of care therapies included: Dara-VCd, Dara-Vd, Dara-VRd, Dara-Dex, Dara-Cd, Dara-Pom-Dex, Bendamustine-Dex Source: Bazarbachi AH et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. Am J Hematol. 2024 Nov;99(11):2225-2228. doi: 10.1002/ajh.27450. Epub 2024 Aug 3. PMID: 39096115. Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. Landau H et al. Initial Safety and Efficacy Data from Nexicart-2, the First U.S. Trial of a CAR-T (NXC-201) in Relapsed or Refractory (R/R) Light Chain (AL). ASH 2025. 89% complete response rate, potentially increasing to 98% (NEXICART-2 45 patients)
Page 12
What that can mean for the patient… Life becomes normal again. A deep breath that reaches the bottom of the lungs. A walk that doesn't end at the mailbox. A normal heartbeat again. 12
Page 13
Era 4 (2010-2019) Era 3 (2000-2009) Expected 3,000 NXC-201 patients/year R/R AL Amyloidosis The Multi-Billion Dollar Opportunity MULTI-BILLION-DOLLAR OPPORTUNITY $588K 2026 Carvykti/BCMA CAR-T Pricing Note: Future management expected pricing represented on this page Note: Prevalence up to 38,000 according to Quock T et al, Epidemiology of AL amyloidosis: a real-world study using US claims data. Blood 2018. Site numbers are illustrative. Source: Mayo staging: 1) Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. ASCT: 2) Bomsztyk J et al, Recent guidelines for high-dose chemotherapy and autologous stem cell transplant for systemic AL amyloidosis: a practitioner’s perspective. Expert Review of Hematology 2022. 3) Gustine J et al, Predictors of hematologic response and survival with stem cell transplantation in AL amyloidosis: A 25-year longitudinal study. AJH 2022. Incidence and prevalence: 4) Laires P. et al. Incidence and Prevalence of Light Chain Amyloidosis in the United States in 2019-2021 Using Optum EHR Data. Nature 2025. 5,386 = 20.2 incidence per U.S. adults. 20.2 = 16.7 per million U.S. adults in 2021 cited in Laires etal. grown to 20.2 over 5 years at half the Laires et al. cited CAGR (7.7% / 2 = 3.9%). 5) Average survival derived from Staron A, et al. Marked progress in AL amyloidosis survival: a 40-year longitudinal natural history study. Blood Cancer Journal. 2021;11:139. Daratumumab: 6) Bellofiore C, et al. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematol Oncol. 2024. 7) Chakraborty R et al, Reduced early mortality with Daratumumab-based frontline therapy in AL amyloidosis: A retrospective cohort study. AJH 2024. 8) Bazarbachi AH et al. Timing and outcomes of second-line therapy in the era of daratumumab-based frontline therapy in AL amyloidosis. Am J Hematol. 2024 Nov;99(11):2225-2228. doi: 10.1002/ajh.27450. Epub 2024 Aug 3. PMID: 39096115. 9) Carvykti average selling price according to CMS. Accessed 6/19/2026. 13 IncidencePrevalence AL Amyloidosis Overall Survival 5,386 × 5.9 years (average survival) = 31,777 ~20% ASCT eligible2 Subtract 4% Cardiac stage 3b1 (not eligible for NXC-201) • ~35% of patients on Darzalex combos reach a CR in the first line of therapy • 8% of all patients in long-term remission with ASCT (20%*40%3 = 8%) … Of which, 3,447 become R/R each year Existing therapies ~80% Darzalex combo eligible 30,506 patients eligible for treatment with NXC- 201 in the U.S. 5,386 annual incidence4 Median: 4.6 years Number of Treating Sites 20 60 Site Build Up Average: 5.9 years (Expected)
Page 14
The Road Ahead Prior 2Q25 3Q25 4Q25 1Q26 Q3 26 NXC-201 U.S. NEXICART-2 Trial with Registration al Design Other NXC-201 U.S. NEXICART-3 Front-Line ✓ Secured rights to NXC-201, N-GENIUS platform from ex- U.S. university ✓ Reported ex-U.S. NEXICART-1 AL Amyloidosis data at ASGCT 2023, ASH 2023, ASGCT 2024, ASH 2024, JCO published 2024 ✓ FDA Orphan Drug Designation (ODD) and Regenerative Medicine Advanced Therapy (RMAT) Designation ✓ Mentioned in New England Journal of Medicine (NEJM) AL Amyloidosis Review ✓ NEXICART-2 U.S. AL Amyloidosis clinical trial first 6 patients dosed; first patient at Memorial Sloan Kettering Cancer Center (met guidance) ✓ Reported first 10 patients U.S. NEXICART-2 AL Amyloidosis clinical data Q2 2025 at ASCO 2025 ✓ FDA Breakthrough Therapy Designation granted in January 2026 ✓ Reported first 20 patients U.S. NEXICART-2 AL Amyloidosis clinical data at ASH 2025 ✓ May 2026 update: additional follow up on ASH 2025 patients ✓ Reported 45 patients Sep 2026 Trial Initiation Expected All 45 patients 1-year follow-up update Planned BLA Submission for FDA Approval Phase 1 interim readout ASCO oral presentation All 45 patients Next Update Late Sep 2026 Enrollment complete: 45 total patients March 2026 NXC-201 Initial Clinical Data in Other Serious Diseases 1H 27 14 ✓
Page 15
Note: Future management expected pricing represented on this page 1. Darzalex annual run rate is $4.2Bn * 4 quarters = $16.8bn (https://www.sec.gov/ix?doc=/Archives/edgar/data/0000200406/000020040626000153/jnj-20260628.htm#fact-identifier-1919). 5,386 new cases AL / (SEER New Cases MM in 2025 36,110) = 14.9% * $16.8bn = $2.5bn Darzalex sales into AL/year. 2. In 2025, 17.57% of Darzalex administered patient days are on AL or AL+MM. 17.57%*$16.8bn = $2.95bn Darzalex sales into AL. (Immx database covers EHR+Claims for >130M U.S. population >20k clinics, >900 hospitals) 3. AU healthcare expenditures indicate that Jul 2024- Jun 2025, AU$211M spent on Darzalex, of which $38.2M was spent on AL = 18.1% of Darzalex $ spent on AL, in-line with the following). 18.1% * $16.8bn annual run rate = $3bn of Darzalex expenditure in AL per AU Jul 2024-Jun2025 analogy. (https://www.pbs.gov.au/statistics/expenditure-prescriptions/2024-2025/Expenditure-prescriptions-report-tables-2024-25.PDF) (https://www.pbs.gov.au/industry/listing/participants/public-release-docs/2025-10/daratumumab-AL-amyloidosis-DUSC-PRD-2025-10-final.PDF) 20 high-prescribing Sites in existing Immix clinical trial Commercial 15 Darzalex AL Amyloidosis estimated annual sales: $2.5-3.1bn (of $16.8bn annual run rate global Darzalex sales) $2.5 bn Epidemiology1 (14.9% of Darzalex annual sales) $3.0 bn EHR + Claims2 (17.5% of Darzalex annual sales) $3.1 bn Australia Darzalex Expense AUFY24-25 3 (18.1% of Darzalex annual sales)
Page 16
16 A World Class Team Dedicated To Saving Lives Ilya Rachman, MD, PhD Chief Executive Officer Gabriel Morris President, Chief Financial Officer Karin McIntosh Head of Regulatory Affairs David He, Head of Technical Operations Oleg Evgrafov, Head of Quality Amanda Squires Head of Clinical Operations Michael Grabow Chief Commercial Officer 16 David Marks, MBBS, PhD Chief Medical Officer
Page 17
We believe we are on the brink of turning despair into hope Success here opens the door to treating other serious diseases 17
Page 18
18 Study design • Open-label, single-arm, multi-site phase 1/2 study • n=45 patients Key criteria Outcome measures Inclusion •AL Amyloidosis patients exposed to at least 1 line of therapy including a CD38 monoclonal antibody and proteosome inhibitor Exclusion •Prior anti-BCMA directed therapy •Cardiac: Mayo stage 3b, NYHA stage III/IV •Concomitant Multiple Myeloma • Safety • Efficacy: Complete hematologic response (CR) NEXICART-2 U.S. Relapsed/Refractory AL Amyloidosis Trial (NCT06097832) Note: Complete Response according to consensus recommendations in AL amyloidosis (Palladini, et al. 2012. "Consensus guidelin es for the conduct and reporting of clinical trials in systemic light -chain amyloidosis." Leukemia 26(11): 2317 -2325.) U.S. TRIAL WITH REGISTRATIONAL DESIGN, ENROLLMENT COMPLETED
Page 19
19 NEXICART-2 (U.S.) Baseline Characteristics: Representative of U.S. R/R AL Amyloidosis Patient Population * Excludes patients enrolled exclusively on M-spike Note: Data cut-off as of August 04, 2026 NEXICART-2 clinical data CART Cell Dose (x106) 150 (n=3) 450 (n=42) Age, median years (range) 67 (56-82) 65 (47-82) Sex, female (%) 2 (67%) 18 (43%) Number of prior lines of therapy, median (range) 4 (2-6) 3 (1-10) Had prior stem cell transplant (yes), n (%) 2 (67%) 15 (36%) Follow-up (days) 282 (90-594) Last 25 patients: 200 (103-376) dFLC (mg/L)* 45 (24-65) 65 (22-310) NYHA Stage 1 (1-2) 1 (1-2) NT-proBNP, median ng/L (range) 560 (146-1,297) 355 (36-6,088) Creatinine, median (mg/dL) (range) 1.1 (0.7-2.2) 1.0 (0.0-2.1) Proteinuria (mg/24 hrs), median (range) 143 (0-3,032) 165 (0-10,274) Organ involvement at enrollment, n (%) Cardiac 2 (67%) 26 (62%) Renal 1 (33%) 16 (38%) Hepatic 0 4 (10%) Cardiac risk stage 3a at diagnosis, n (%) 0 10 (24%) Cardiac risk stage 3a at enrollment, n (%) 1 (33%) 7 (17%) First 20 patients: 474 (90-769) 741 (685-769)
Page 20
20 -100% -80% -60% -40% -20% 0% 1 2 4 5 6 7 8 9 12 13 14 15 1617 18 19 20 212223 24 26 27 28 29 31 32 33 34 35 36 37 38 39 40 42 43 45 46 3 10 11 25 30 41 Patients Withd rawn Time to response (days) 14 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 25 25 7 8 7 7 7 7 7 7 7 7 7 26 7 7 14 15 7 14 7 15 7 160 146 15 Pending Follow-up (days) 769741473127 594 566 559 316 496 90 474 277446433411 411 404 376 369 176200 320 313 285 285 278 257 257 251 194 194 187 188 166 166 131 131 124 124 685 509 502 348 278 159 Disease Marker Normal ( ) at best response Note: Data cut-off as of August 04, 2026. dFLC: difference in free light chain (disease marker). Renal response based on AL Amyloidosis consensus criteria for renal response (Palladini G et al 2014 doi: 10.1182/blood-2014-04-570010). Most recent available dFLC reading for patient NX2-001 as of day 726. For patient NX2-002, as of day 622. 9 out of 9 cardiac organ responses evaluable – NX2-006, NX2-008 , NX2-011, NX2-015, NX2-024, NX2-029, NX2-032, NX2-038, NX2-039; 11 out of 11 renal responses evaluable – NX2-003, NX2-010, NX2-015, NX2-017, NX2-018, NX2-020, NX2-028, NX2-030, NX2-040, NX2-043, NX2-045. AL Amyloidosis disease markers on line graph: All patient data is dFLC (left-hand side vertical axis), except for patients NX2-003, NX2-010, and NX2-011, NX2-025, NX2-030, NX2-041 which are m-spike (right-hand side vertical axis). Patient NX2-013 withdrawn from study on D+90 days due to hematologic progression. NX2-011, NX2-025, NX2-041 M-spike igg type (longer half-life) NX2-003, NX2-010. NX2-030 M-spike iga type (shorter half-life). – denotes not eligible. NEXICART-2 (U.S.) Efficacy: Rapid Normalization of Diseased Light Chains within ~First Week NEXICART-2 clinical data dFLC Percentage Decline by Day (Best Response) Pending NX2- 1 2 4 5 6 7 8 9 12 13 14 15 16 17 18 19 20 21 22 23 24 26 27 28 29 31 32 33 34 35 36 37 38 39 40 42 43 44 45 3 10 11 25 30 41 Organ Response Eligible? - - - - - - - - - - - - - - - - - - - - - - - - - Organ Response Recorded? - - - No n Re sp o n d e r - - - - - - - - - - - - - - - - - - - - - - MRD- Negative Day 25? Wit hdr awn Pen ding Pos • Organ responses in 95% (20/21) evaluable (100% , 92% ) -100% -100% -100% -100% -100% -98% -100% -100% -100% -91% -100% -100% -93% -100% -100% -100% -100% -100% -100% -99% -100% -100% -100% -100% -100% -100% -100% -100% -100% -100% -98% -100% -100% -100% -100% -99% -96% -99% -100% -100% -100% -100% -100% -100% -80% -100% -90% -80% -70% -60% -50% -40% -30% -20% -10% 0% 0 1 2 0 50 100 150 200 250 300 1 2 4 5 6 7 8 9 12131415161718192021222324262728293132333435363738394042434445 3 1011253041 300 Patient NX2- M-spike (g/dL) Disease Burden at NXC-201 Dosing: dFLC (mg/L) After NXC-201, Reduction in dFLC (mg/L)/ M-Spike (Best Response) Normal zone
Page 21
21 Days 700100 200 300250 35050 150 400 450 500 550 600 650 P2 P3 P4 P5 P6 P7 P8 P9 P10 P11 P12 P13 P14 P15 P16 P17 P18 P19 P20 P1 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 POS 10-5 Withdrawn Normal Withdrawn Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR Withdrawn CR P22 P23 P24 P25 P26 P27 P28 P29 P30 P31 P32 P33 P34 P35 P36 P37 P38 P39 P40 P21 Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal Normal CR CR CR CR CR CR CR CR CR CR P41 P42 P43 P44 P45Normal Normal Normal Normal CR Pending Pending Pending Pending Normal Above normal NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 Pending NEG 10-5 NEG 10-5 750 CR CR CR NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 Normal CR CR CR CR CR CR NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 NEG 10-5 CR Normal NEG 10-4 Normal NEXICART-2 (U.S.) Clinical Activity: 89% Complete Responses (CR) – 40/45 Patients Complete response (CR) is FDA Regulatory Endpoint Complete Response Note: Data cut-off as of August 04, 2026. Complete Response according to consensus recommendations in AL amyloidosis (Palladini, et al. 2012. "Consensus guidelines for the conduct and reporting of clinical trials in systemic light -chain amyloidosis." Leukemia 26(11): 2317-2325.) Patients NX2-003, NX2-010, and NX2-011, NX2-025, NX2-030, NX2-041 enrolled on M-Spike. NX2-011, NX2-025, NX2-041 M-spike igg type (longer half-life) NX2-003, NX2-010. NX2-030 M-spike iga type (shorter half-life). Patient NX2-013: Withdrawn due to progression. No treatment-related deaths were recorded. Four deaths occurred in complete response (CR) (none treatment related) due to: a rec urrent dialysis catheter infection; accidental fall leading to aspiration pneumonia respiratory failure; pre -existing hypokalemia and subsequent arrythmia due to non -compliance with potassium supplementation; pre -existing pharyngeal soft tissue amyloid inf iltration causing dysphagia resulting in chronic aspiration pneumonia and respiratory failure; (NX2 -005, NX2-004, NX2-024, NX2-023). MRD: 10-5 denotes -5 or higher; 10-4 denotes -4 or higher Patients NX2-009 consent withdrawn in complete response (CR) due to treatment for preexisting, unrelated disease ; NX2-015 consent withdrawn in complete response (CR) due to travel Source: Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. Patients: NX2- 01 02 03 04 05 06 07 08 09 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 Time to response (days) 14 7 15 7 7 7 7 7 7 7 160 7 7 7 7 7 7 7 7 7 7 25 25 7 146 8 7 7 7 15 7 7 7 7 7 7 26 7 7 14 Pending 15 7 14 7 Hematologic response CR CR CR CR CR CR CR CR CR CR CR CR Withdra wn CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR CR Pending CR CR CR Pending CR CR Pending Pending Existing investigator’s choice therapies 0-10% complete response rate No FDA Drugs approved 1 year 2 year Already MRD(-) Already MRD(-) Already MRD(-) Already MRD(-) • Organ responses in 95% (20/21) evaluable (100% , 92% ) MRD at D + 25 Light Chain Status at Best Response Best Hematologic Response MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate to 98% NEXICART-2 clinical data Median time to CR: 3 months Hematologic response
Page 22
22 Median day 7: toxic light chains normalize Day 25: MRD negativity Deep, Rapid, Sustained Organ Responses Observed to date in NEXICART-2 Note: Consensus Renal response based on AL Amyloidosis consensus criteria for renal response (Palladini G et al 2014). Cardiac response based on AL Amyloidosis consensus criteria for cardiac response (Comenzo RL et al 2012). Cardiac biomarker: NT-proBNP; renal biomarker: proteinuria. Source: Palladini et al., Journal of Clinical Oncology 2012. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurements and Cardiac Biomarkers: Impact on Survival Outcomes. Muchtar et al., Leukemia 2018. New Criteria for Response to Treatment in Immunoglobulin Light Chain Amyloidosis Based on Free Light Chain Measurements and Cardiac Biomarkers: Impact on Survival Outcomes. NEXICART-2 clinical data Organ Response Eligibility Thresholds at Enrollment Cardiac NT-proBNP > 650 ng/L Renal proteinuria > 0.5 g/24 hours Response Criteria Post Treatment Cardiac >30% and >300 ng/L decrease Renal ≥30% decrease or a drop in proteinuria below 0.5g/24 hours-100% -90% -80% -70% -60% -50% -40% -30% -20% -10% 0% Day 0 Day 25 Month 2 Month 3 Month 4 Month 5 Month 6 Month 8 Month 10 Month 12 Month 15 Month 18 Cardiac Renal Median Organ Disease Marker Change from Baseline After NXC-201: Cardiac and Renal Response Threshold for organ response: 30% biomarker decline “In all organs, the deeper the organ response achieved, the longer the survival.” – Eli Muchtar, M.D. Associate Professor Mayo Clinic doi: 10.1038/s41375-018-0060-x “Response and progression of NT-proBNP significantly affected survival both at 6 and at 3 months” – Giovanni Palladini, M.D., Ph.D. Professor, Head and Director of the Medical Staff Università di Pavia doi: 10.1200/JCO.2011.37.7614 Representative Sequence of Events for NEXICART-2 Cardiac: NT-proBNP Renal: Proteinuria/24 hours Median Time to Organ Response After NXC-201 Cardiac 26 Days Renal 59 Days Median Time to Complete Response After NXC-201 3 months • Organ responses in 95% (20/21) evaluable (100% , 92% )
Page 23
23 NEXICART-2 (U.S.) TEAE Summary • No patient experienced a Grade 5 TEAE across any cohort related to NXC-201 Note: Data cut-off as of August 04, 2026. CRS and ICANS reported according to ASTCT Consensus Grading (Lee et al. 2019). TEAE = treatment-emergent adverse events. Green background denotes <10%. CRS = cytokine release syndrome. LFT = liver function test. CART Cell Dose (x106) 150 (n=3) 450 (n=42) Grade Any Grade Grade >3 Any Grade Grade >3 Any TEAE, n (%) 3 (100%) 3 (100%) 45 (100%) 36 (92%) CRS n (%) 1 (33%) 0 37 (88%) 0 (0%) Onset, days (range) 2 (n=1) none 1 (1-8) none Duration, days (range) 2 (n=1) none 1 (1-5) none Neurotoxicity, n 0 (0%) 0 (0%) 0 (0%) 0 (0%) Neutropenia, n 3 (100%) 3 (100%) 28 (66%) 24 (57%) Febrile Neutropenia, n 0 (0%) 0 (0%) 1 (2%) 1 (2%) Infections, n 0 (0%) 0 (0%) 3 (7%) 1 (2%) Anemia, n 1 (33%) 1 (33%) 9 (21%) 7 (16%) Thrombocytopenia, n 0 (0%) 0 (0%) 9 (21%) 5 (11%) LFT abnormalities, n 0 (0%) 0 (0%) 6 (14%) 4 (9%) Fatigue, n 0 (0%) 0 (0%) 15 (35%) 0 (0%) ≥ Grade 2 cardiac events, n 0 (0%) 0 (0%) 1 (2%) 0 (0%) NEXICART-2 clinical data
Page 24
24 Complete Response Rate Improving Over Time Subject # NX2- 001 CR CR CR CR 002 CR CR CR CR 003 CR CR CR CR 004 Pending (already MRD (-)) CR CR CR 005 CR CR CR CR 006 CR CR CR CR 007 Pending (already MRD (-)) CR CR CR 008 CR CR CR CR 009 Pending (already MRD (-)) CR CR CR 010 CR CR CR CR 011 Pending (already MRD (-)) CR CR 012 Pending (already MRD (-)) CR CR 013 -- -- -- 014 CR CR CR 015 CR CR CR 016 Pending (already MRD (-)) CR CR 017 CR CR CR 018 CR CR CR 019 Pending (already MRD (-)) CR CR 020 CR CR CR 021 CR 022 CR 023 CR 024 CR 025 CR 026 CR 027 CR 028 CR 029 CR 030 CR 031 CR 032 CR 033 CR 034 CR 035 CR 036 CR 037 Pending (already MRD (-)) 038 CR 039 CR 040 CR 041 Pending (already MRD (-)) 042 CR 043 CR 044 Pending (already MRD (-)) 045 Pending (already MRD (-)) with May 2026 update Data Cutoff: April 11, 2025 November 13, 2025 May 14, 2026 August 4, 2026 CR RATE: 95% 75% 70% Subject # NX2- Subject # NX2- MRD negativity in bone marrow predicts future complete response, potentially increasing future CR rate up to 98% 89%
Page 25
25 Study design • Randomized 1:1, multi-site phase 3 study • Arm A: NXC-201 • Arm B: DaraCyBorD Key criteria Outcome measures Inclusion •Newly diagnosed AL Amyloidosis patients Exclusion •Cardiac: Mayo stage 3b, NYHA stage III/IV •Concomitant Multiple Myeloma • Primary endpoint: Complete hematologic response (CR) • Safety NEXICART-3 U.S. Newly Diagnosed AL Amyloidosis Trial (NCT07709715) Note: Complete Response according to consensus recommendations in AL amyloidosis (Palladini, et al. 2012. "Consensus guidelin es for the conduct and reporting of clinical trials in systemic light -chain amyloidosis." Leukemia 26(11): 2317 -2325.) PHASE 3 RANDOMIZED CONTROLLED TRIAL –INITIATION PLANNED FOR 1H 2027
Page 26
October 2026 Global Leader in relapsed/refractory AL Amyloidosis
Page 27
27 NXC-201 Median CRS Duration (Days) 1 5 4 8 4 3 Median CRS Onset (Days) 0 1 7 2 1 10 Range CRS Duration (Days) 1-7 1-63 1-97 3-13 1-16 NR Source Blood Adv Publication FDA Label FDA Label S-1 ASH 2023 EHA 2026 Source: Note: Studies not head-to-head Anito-cel /CARTddBCMA “The biggest challenge … has been applicability of these therapies in amyloidosis when the patients are particularly frail and have organ dysfunction … where the key lies in the safety rather the efficacy in a low-volume disease setting is going to be key … ” – Dr. Susan Bal, MD Assistant Professor, Hematology University of Alabama at Birmingham Others are 3-7x higher NXC-201’s short CRS duration, if proven to be safe and effective, makes it uniquely suitable to treat ALA patients (in whom the #1 source of mortality is heart failure) Cardiovascular stress is the key determinant for ability to treat relapsed/refractory ALA patients • Long CRS duration causes extended cardiovascular stress • Other CARTs have 3-7x longer CRS duration Data in Multiple Myeloma D8 BCMA /AUTO8 Median CRS Duration (Days) NXC-201 Tolerability Drives AL Amyloidosis Leadership ALL BCMA CAR-TS ARE NOT CREATED EQUAL ✓ KLN-1010
Page 28
28 NXC-201: Deepest Responses, In Most Heavily Pretreated Population1 2 NXC-201 Etentamig Linvoseltamab Teclistamab NXC-201: Later Phase … n 45 34 20 52 Phase Phase 2 Phase 1 Phase 2 Retrospective Dosing Frequency 1-Time 24 Months (QW4) Weekly 8W , QW4 40W Monthly … in heavily pre- treated population … Median Prior Lines 3 2 1 2 Prior CD38 monoclonal antibody? 100% 100% 60% 100% Prior ASCT ? 38% 21% NR NA … with independent review committee (IRC) adjudicated responses … Complete Response Rate 89% (up to 98% with MRD-negativity) 91% 90% (18/20) 41% Independent Review Committee (IRC)? Yes(1) No(2) No No … faster, deeper, and more frequent downstream organ responses Cardiac Organ Responses 100% 43% 50% 65% Median Time to Cardiac Response 0.9 Months 2.5 Months NA NA Renal Responses 92% 54% 73% 78% ICANS 0% 0% 5% 0% Treatment-Related Infections (Any Grade) 7% 77% 85% Total infection events: 104 Treatment-Related Infections (>Grade 3) 2% 6% 25% 42% (deaths n=6 [12%]) IVIG Prophylaxis NA 100% NA 83%(3) ✓ Source: Landau H. et al. ASH 2025 with May 2026 update. Kastritis, et al 2026 EHA P1 Dose Escalation of Etentamig. EHA Library. Kastritis E. 06/12/2026; 4206763; S209. Carpinteiro A, et al. Teclistamab in relapsed/refractory light chain amyloidosis: A retrospective multicenter study by the German Society for Amyloid Diseases. Hemasphere. 2026 Jun 16;10(6):e70389. doi: 10.1002/hem3.70389. PMID: 42311430; PMCID: PMC13270341.; Regeneron Pharmaceuticals, Inc. Lynozyfic (linvoseltamab) Monotherapy Demonstrates Deep and Rapid Responses in All Treated Patients with Second -Line-Plus Systemic Amyloid Light Chain Amyloidosis. May 21, 2026. Accessed August 21, 2026. Note: Q4W: every 4 weeks. Linvoseltamab deaths n=2. NXC-201 organ response denominator reflects patients eligible for organ response; etentamig and teclistamab organ response denominator reflects patients with involved organ; (1) Two patients evaluated by site; (2) AbbVie ASH 2025 abstract. (3) Substitution with intravenous or subcutaneous immunoglobulins (IRT). Immix infection rate reflects infections deemed related to treatment. Note: Studies not head-to-head. X XX Safety
Page 29
29 ~$1bn $150 $87 $479 $242 $544 $72 $0 $200 $400 $600 $800 $1,000 2021 2022 2023 2024 Launch Year 2025 2026 2027 Market Reference: Commercialization Cost Trend Over Time COGS + SG&A(1) in Launch Year New launches from small caps in $72mm - $112mm range Gilead highlighted cell therapy business was close to break-even in 2024, with sales ~$1.5bn (2) (4) Or Before Zynteglo 2022 Carvykti 2022 $1,200 Yescarta 2017 $528(3) Casgevy 2023 Elevidys 2023 Roctavian 2023 $50 Omisirge 2023 Tecelra 2024 Zevaskyn 2025 AMT-130 $112 $87 IMA203 Note: $ in millions; (1) Calculated as COGS and SG&A in launch year; (2) Represents COGS of Carvykti shared between J&J and Legend (50/50 profit share) and Legend SG&A multiplied by 2 to more closely reflect total costs; (3) Represents total costs for Casgevy between CRISPR and Vertex; (4) Represents total costs for Roctavian, disclosed as R&D + SG&A
Page 30
NEXICART-1 (Israel): Normalization of Toxic Free Light Chains 30 Days after Dosing BACKGROUND: IMMIX LICENSED-IN NXC-201 BASED ON EX-U.S. DATA SHOWING PLASMA CELL ELIMINATION IN RELAPSED/REFRACTORY AL AMYLOIDOSIS(MENTIONED IN NEJM) Note: Data cut-off as of December 9, 2024. As presented in Journal of Clinical Oncology. Patient 13 decline illustrative, dFLC decline excluded from publication line graph. Patients 6 and 8 not a CR due to immunofixation Source: E Lebel et al. Efficacy and Safety of Anti-BCMA Chimeric Antigen Receptor T -Cell (CART) for the Treatment of Relapsed and Refractory AL Amyloidosis. Presentation. ASH 2024. Zanwar S, et al. Treatment patterns for AL amyloidosis after frontline daratumumab, bortezomib, cyclophosphamide, and dexamethasone treatment failures. Leukemia 2024. 0 150 300 1 2 3 4 5 9 10 12 13 14 15 16 6 7 8 11 Disease Burden Prior to R/R NXC-201 Dosing: dFLC (mg/L) -99% -99% -97% -99% -98% -83% -98% -98% -98% -97% -98% -86% -98% -68% -87% -2% -100% -80% -60% -40% -20% 0% % Decline in disease burden (dFLC) after NXC-201 is dosed as median 4th line therapy Patient ✓✓✓✓✓✓✓✓✓✓✓✓ Not CR Normal zone “An early and deep hematologic response has been found to lead to significantly prolonged survival” – Vaishali Sanchorawala, M.D. Professor, Hematology and Oncology Director, Amyloidosis Center at Boston University School of Medicine Director, Stem Cell Transplantation at Boston Medical center doi: 10.1056/NEJMra2304088 Current investigator’s choice therapies 0-10% complete response rate No FDA Drugs approved NXC-201 75% (12/16) complete response rate (NEXICART-1)
Page 31
31 Up to 91% (=18+64+9) of AL Amyloidosis Patients Receiving Frontline Dara-Cy-Bor-D Require 2nd Line Therapy within 12 Months based on peer studies Note: Example 100 newly diagnosed patient scenario based on sources listed below. Dara-Cy-Bor-D: daratumumab, cyclophosphamide, bortezomib, dexamethasone Source: 1) Kastritis E, et al. ASH 2024 2) Bellofiore C, et al. A real-life study of daratumumab combinations in newly diagnosed patients with light chain (AL) amyloidosis. Hematol Oncol. 2024 (1) (2) (2) 100 newly diagnosed 82 reach 6 cycles(1) 18 don’t reach 6 cycles 18 (22%) reach CR(2) 64 (78%) don’t reach CR 9 (50%) relapse <12M(2)
Page 32
32 100% of doses manufactured successfully, median vein-to-vein time of 14 days Notes: Source: Based on Company internal metrics. 0 2 4 6 8 10 12 14 16 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 43 44 45 Days Patient
Page 33
33 Source: Mouhieddine TH, Anderson KC. Treatment Decisions in Multiple Myeloma. N Engl J Med. 2026 Sep 10;395(10):992-1008. doi: 10.1056/NEJMra2605253. PMID: 42715563. “When feasible, CAR T cells should be …used early, whereas bispecific antibodies are preserved for later therapy.” “The IMWG immunotherapy committee accordingly recommends early collection of CAR T cells, ideally before bispecific antibody exposure” “Previous bispecific antibody exposure appears to reduce subsequent BCMA CAR T-cell efficacy through impaired T-cell fitness and antigen escape, whereas CAR T-cell therapy followed by bispecific antibody therapy is less detrimental” “Directed T-cell redirection [bispecifics] can be associated with downregulation, mutation, or genetic deletion of BCMA.” – Kenneth C. Anderson, M.D. Dana-Farber Cancer Institute doi: 10.1056/NEJMra2605253 Sequencing Matters: CAR-T First, Bispecifics Later PER NEJM 2026: DANA FARBER’S KEN C. ANDERSON CAR-T First Bispecific Later ✓✓ Preferred Sequence
Page 34
34 AL AL Amyloidosis Diagnoses Have Increased, Driven by Awareness and ATTR Diagnosis Steps Source: 1) Alnylam investor presentation; 2) Anonymized electronic health records for over 100 million Americans, AL and ATTR values determined from one ICD code diagnosis relative number Amyloidosis (both ATTR and AL) present as heart failure1 Positive Negative Every ATTR Diagnosis Requires AL Light Chain Test (to Rule Out AL Amyloidosis) US AL Diagnoses are Trending Up, Paralleling ATTR2 0 2 4 6 8 10 2018 2019 2020 2021 2022 2023 2024 2025 Thousands of patients Year Distinct diagnosed patients AL ATTR patisiran • 2018 tafamidis • 2019 daratumumab • 2021 vutrisiran • 2022 acoramidis • 2024 vutrisiran CM • 2025 AL amyloidosis confirmation steps: biopsy ATTR confirmation steps: nuclear scintigraphy/biopsy ATTR AL Amyloidosis light chain testing Step 1 (to diagnose either AL or ATTR) Step 2 2 AL ATTR Relative Diagnosis Volume Each line indicates a drug approval: orange for ATTR; blue for AL amyloidosis
Page 35
October 2026 Global Leader in Relapsed/Refractory AL Amyloidosis This presentation contains NEXICART- 2 clinical data update on pages 19-24